Eterna Therapeutics
ERNA
8 hedge funds and large institutions have $6.21M invested in Eterna Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
39% more capital invested
Capital invested by funds: $4.46M → $6.21M (+$1.75M)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$112K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $2.79M | – | – | – |
|
|
NSIM
2
North Star Investment Management
Chicago,
Illinois
| $1.72M | +$1.5M | +13 | New |
|
|
EAM
3
Eagle Asset Management
St Petersburg,
Florida
| $775K | – | – | – |
|
4
Renaissance Technologies
New York
| $294K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $182K | – | – | – |
|
|
CA
6
Callahan Advisors
Houston,
Texas
| $162K | – | – | – |
|
7
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $130K | – | – | – |
|
8
Vanguard Group
Malvern,
Pennsylvania
| $120K | – | – | – |
|
9
BlackRock
New York
| $25K | – | – | – |
|
10
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $9K | – | – | – |
|
11
UBS Group
Zurich,
Switzerland
| $3K | – | – | – |
|
12
Barclays
London,
United Kingdom
| $1K | – | – | – |
|
|
LTFS
13
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
14
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
15
Morgan Stanley
New York
| $1K | – | – | – |
|
|
16
Goldman Sachs
New York
| – | -$112K | -1 | Closed |
|
ERNA Hedge Fund Activity: Q1 2017 in Review
8 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2017, worth a combined $6.21M — up 39% from $4.46M a quarter earlier.
Fund positioning in ERNA was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was North Star Investment Management, opening a new position worth an estimated $1.5M. The largest seller was Goldman Sachs, exiting entirely with an estimated $112K sold.
- 8 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $6.21M of Eterna Therapeutics stock for Q1 2017, up 39% quarter-over-quarter.
- 1 fund opened new Eterna Therapeutics positions in Q1 2017 and 1 closed out, a net change of 0 holders.
- The largest Eterna Therapeutics buyer in Q1 2017 was North Star Investment Management, an estimated $1.5M added.
- The largest Eterna Therapeutics seller in Q1 2017 was Goldman Sachs, an estimated $112K sold.
Based on aggregated 13F filings for Q1 2017.